{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T06:18:59Z","timestamp":1764829139672,"version":"3.37.3"},"reference-count":14,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T00:00:00Z","timestamp":1697155200000},"content-version":"vor","delay-in-days":285,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100016348","name":"Kyowa Kirin Pharmaceutical Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016348","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Parkinsonism & Related Disorders"],"published-print":{"date-parts":[[2023]]},"DOI":"10.1016\/j.prdoa.2023.100224","type":"journal-article","created":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T04:40:10Z","timestamp":1697258410000},"page":"100224","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Istradefylline effects on tremor dominance (TD) and postural instability and gait difficulty (PIGD)"],"prefix":"10.1016","volume":"9","author":[{"given":"Yasar","family":"Torres-Yaghi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobutaka","family":"Hattori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivier","family":"Rascol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Nakajima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shelby M.","family":"King","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihisa","family":"Mori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernando","family":"Pagan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.prdoa.2023.100224_b0005","series-title":"The Adenosinergic System: A Non-Dopaminergic Target in Parkinson\u2019s Disease","first-page":"273","article-title":"The story of istradefylline\u2014the first approved A2A antagonist for the treatment of Parkinson\u2019s disease","author":"Mori","year":"2015"},{"key":"10.1016\/j.prdoa.2023.100224_b0010","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/B978-0-12-801022-8.00004-0","article-title":"Mode of action of adenosine A2A receptor antagonists as symptomatic treatment for Parkinson's disease","volume":"119","author":"Mori","year":"2014","journal-title":"Int. Rev. Neurobiol."},{"issue":"3","key":"10.1016\/j.prdoa.2023.100224_b0015","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1080\/14737175.2021.1880896","article-title":"Istradefylline \u2013 a first generation adenosine A2A antagonist for the treatment of Parkinson's disease","volume":"21","author":"Jenner","year":"2021","journal-title":"Expert Rev. Neurother."},{"issue":"4","key":"10.1016\/j.prdoa.2023.100224_b0020","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.3233\/JPD-212672","article-title":"Efficacy of istradefylline, an adenosine A2A receptor antagonist, as adjunctive therapy to levodopa in Parkinson's disease: a pooled analysis of 8 phase 2b\/3 trials","volume":"11","author":"Hauser","year":"2021","journal-title":"J. Parkinsons Dis."},{"issue":"4","key":"10.1016\/j.prdoa.2023.100224_b0025","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.3390\/s18041102","article-title":"Motor subtypes of Parkinson's disease can be identified by frequency component of postural stability","volume":"18","author":"Rezvanian","year":"2018","journal-title":"Sensors (Basel, Switzerland)"},{"issue":"10","key":"10.1016\/j.prdoa.2023.100224_b0030","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1001\/archneur.58.10.1611","article-title":"Functional decline in Parkinson disease","volume":"58","author":"Jankovic","year":"2001","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.prdoa.2023.100224_b0035","unstructured":"NOURIANZ\u2122 (istradefylline) tablets, for oral use. US prescribing information. Bedminster, NJ: Kyowa Kirin Inc.; May 2020."},{"issue":"10","key":"10.1016\/j.prdoa.2023.100224_b0040","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1212\/WNL.40.10.1529","article-title":"The Parkinson Study Group, Variable expression of Parkinson's disease: a base-line analysis of the DATATOP cohort","volume":"40","author":"Jankovic","year":"1990","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.prdoa.2023.100224_b0045","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1016\/j.neuroimage.2010.09.028","article-title":"Parkinson's disease tremor-related metabolic network: characterization, progression, and treatment effects","volume":"54","author":"Mure","year":"2011","journal-title":"Neuroimage"},{"issue":"11","key":"10.1016\/j.prdoa.2023.100224_b0050","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1080\/14656566.2019.1614167","article-title":"Efficacy of istradefylline for gait disorders with freezing of gait in Parkinson's disease: a single-arm, open-label, prospective, multicenter study","volume":"20","author":"Iijima","year":"2019","journal-title":"Expert Opin. Pharmacother."},{"issue":"Suppl 1","key":"10.1016\/j.prdoa.2023.100224_b0055","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1016\/j.parkreldis.2020.09.025","article-title":"How do adenosine A2A receptors regulate motor function?","volume":"80","author":"Mori","year":"2020","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.prdoa.2023.100224_b0060","doi-asserted-by":"crossref","first-page":"471","DOI":"10.3389\/fneur.2019.00471","article-title":"Alteration of tremor dominant and postural instability gait difficulty subtypes during the progression of Parkinson's disease: analysis of the PPMI cohort","volume":"10","author":"Lee","year":"2019","journal-title":"Front. Neurol."},{"key":"10.1016\/j.prdoa.2023.100224_b0065","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.parkreldis.2021.05.016","article-title":"The inconsistency and instability of Parkinson's disease motor subtypes","volume":"88","author":"von Coelln","year":"2021","journal-title":"Parkinsonism Relat. Disord."},{"issue":"9","key":"10.1016\/j.prdoa.2023.100224_b0070","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1002\/mds.20513","article-title":"Clinical characteristics in early Parkinson's disease in a central California population-based study","volume":"20","author":"Kang","year":"2005","journal-title":"Move. Disord."}],"container-title":["Clinical Parkinsonism & Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590112523000427?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590112523000427?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,10]],"date-time":"2025-01-10T10:16:30Z","timestamp":1736504190000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2590112523000427"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023]]},"references-count":14,"alternative-id":["S2590112523000427"],"URL":"https:\/\/doi.org\/10.1016\/j.prdoa.2023.100224","relation":{},"ISSN":["2590-1125"],"issn-type":[{"type":"print","value":"2590-1125"}],"subject":[],"published":{"date-parts":[[2023]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Istradefylline effects on tremor dominance (TD) and postural instability and gait difficulty (PIGD)","name":"articletitle","label":"Article Title"},{"value":"Clinical Parkinsonism & Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prdoa.2023.100224","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100224"}}